» Articles » PMID: 38252511

Optimization of Time Interval for the Measurement of Plasma Lipids for Cardiovascular Disease Risk Assessment

Overview
Specialty Molecular Biology
Date 2024 Jan 22
PMID 38252511
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lipid testing for atherosclerotic cardiovascular disease (ASCVD) risk is often performed every 4-6 years, but we hypothesized that the optimum time interval may vary depending on baseline risk.

Research Design And Methods: Using lipid values and other risk factors from the National Health and Nutrition Examination Survey (NHANES) ( = 9,704), we calculated a 10-year risk score with the pooled-cohort equations. Future risk scores were predicted by increasing age and projecting systolic blood pressure (SBP) and lipid changes, using the mean-percentile age group change in NHANES for SBP ( = 17,329) and the Lifelines Cohort study for lipids ( = 133,540). The crossing of high and intermediate-risk thresholds were calculated by time to determine optimum intervals for lipid testing.

Results: Time to crossing risk thresholds depends on baseline risk, but the mean increase in the risk score plateaus at 1% per year for those with a baseline 10-year risk greater than 15%. Based on these findings, we recommend the following maximum time intervals for lipid testing: baseline risk < 15%: 5-years, 16%: 4-years, 17%: 3-years, 18%: 2-years, and 19%: ≤1-year.

Conclusions: Testing patients for lipids who have a higher baseline risk more often could identify high-risk patients sooner, allowing for earlier and more effective therapeutic intervention.

References
1.
Dhingra R, Vasan R . Age as a risk factor. Med Clin North Am. 2012; 96(1):87-91. PMC: 3297980. DOI: 10.1016/j.mcna.2011.11.003. View

2.
Dayimu A, Wang C, Li J, Fan B, Ji X, Zhang T . Trajectories of Lipids Profile and Incident Cardiovascular Disease Risk: A Longitudinal Cohort Study. J Am Heart Assoc. 2019; 8(21):e013479. PMC: 6898842. DOI: 10.1161/JAHA.119.013479. View

3.
Ford I, Murray H, McCowan C, Packard C . Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study. Circulation. 2016; 133(11):1073-80. PMC: 4894764. DOI: 10.1161/CIRCULATIONAHA.115.019014. View

4.
Goff Jr D, Lloyd-Jones D, Bennett G, Coady S, DAgostino R, Gibbons R . 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 129(25 Suppl 2):S49-73. DOI: 10.1161/01.cir.0000437741.48606.98. View

5.
Karmali K, Goff Jr D, Ning H, Lloyd-Jones D . A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014; 64(10):959-68. DOI: 10.1016/j.jacc.2014.06.1186. View